Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 79.78

0.0%

Dec 31 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (1752)	12/6/2007 3:34:50 PM
From: Jibacoa	Read Replies (2) of 3722

MNTA Is now up 14.81% for the day. bigcharts.marketwatch.com Back on Nov 5, it announced that Sandoz had received a letter from the FDA stating that the ANDA for Enoxaparin Sodium Injection was not approvable on its present version. According to the FDA, all applications for enoxaparin products must address the potential for immunogenicity of the drug product. Craig A. Wheeler, MNTA's CEO said that he believed that, based on their detailed characterization of enoxaparin and the current medical and scientific literature,they could address the FDA's concerns & be able to move the drug forward in conjunction with Sandoz. At any rate,with the stock selling just a little above BV, the short position still around 6x its AvgDV in spite of a 75% coverage in the last month & the insiders holding > 20% & institutions >70%, the R/R isn't bad at present levels.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next